跳至主要内容
临床试验/NCT04933760
NCT04933760Unknown不适用

CV-SQuISH-ED: A Clinical Validation Solving the Question of Inflammation or Sepsis Hastily in the Emergency Department

Cytovale, Inc.4 个研究点 分布在 1 个国家目标入组 599 人开始时间: 2021年5月18日最近更新:
适应症

试验速览

阶段
不适用
入组人数
599
试验地点
4
主要终点
IntelliSep Index versus Retrospective Physician Diagnosis (RPD) per the sepsis 3 definition

研究概览

简要总结

This is a study to evaluate the diagnostic performance of the investigational Cytovale System & IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to the emergency department with signs or suspicion of infection compared to retrospective physician adjudication, per the sepsis 3 definition, of those patients.

详细描述

This is a multi-site prospective study to evaluate the diagnostic performance of the investigational Cytovale System & IntelliSep Test for patients presenting to the Emergency Department with signs or suspicion of infection. The IntelliSep Test is a microfluidic test that measures the biophysical properties of human leukocytes in conjunction with other laboratory findings and clinical assessments to aid in the early detection of sepsis with organ dysfunction occurring within the first three days after the blood sample collection.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years old
  • The first vital sign (any one of: blood pressure, temperature, pulse or respiratory rate) has been recorded in the medical record
  • A 300µl blood sample originally collected in a K2 EDTA (hematology purple top) tube within 4 hours of the first recorded vital sign is available.
  • Sign or suspicion of infection, defined as meeting either of criterion A-1 and A-2 (based on temperature, WBC, heart rate, respiratory rate and/or culture order criteria):

排除标准

  • Patients in whom a palliative care or hospice course is expected during ED visit
  • Self-reported, documented or otherwise known to be actively enrolled on any experimental/investigational therapeutic medication prior to blood collection
  • Self-reported, documented, or known history of a hematologic malignancy (any leukemia, lymphoma, or myeloma), myelodysplastic syndrome, or myeloproliferative disorder
  • Self-reported, documented or otherwise known to receive a chemotherapeutic agent or other excluded medication in the past 3 months (Appendix C)
  • Self-reported, documented or otherwise known to have undergone a hematopoietic stem cell transplant or any solid organ transplant
  • Patients transferred to the Emergency Department from another acute care facility
  • Residents or patients of a hospital-based skilled nursing facility

结局指标

主要结局

IntelliSep Index versus Retrospective Physician Diagnosis (RPD) per the sepsis 3 definition

时间窗: 30 days

To validate the diagnostic performance of the investigational Cytovale System \& IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to the emergency department with signs or suspicion of infection, the IntelliSep test score is compared to the non-reference method of retrospective physician adjudication, per the sepsis 3 definition, of those patients.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验